"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 15 | 26 | 41 |
| 1996 | 14 | 27 | 41 |
| 1997 | 16 | 25 | 41 |
| 1998 | 15 | 24 | 39 |
| 1999 | 14 | 20 | 34 |
| 2000 | 27 | 28 | 55 |
| 2001 | 20 | 35 | 55 |
| 2002 | 29 | 44 | 73 |
| 2003 | 37 | 50 | 87 |
| 2004 | 39 | 33 | 72 |
| 2005 | 42 | 40 | 82 |
| 2006 | 61 | 29 | 90 |
| 2007 | 65 | 53 | 118 |
| 2008 | 59 | 60 | 119 |
| 2009 | 70 | 55 | 125 |
| 2010 | 80 | 54 | 134 |
| 2011 | 59 | 46 | 105 |
| 2012 | 33 | 30 | 63 |
| 2013 | 46 | 21 | 67 |
| 2014 | 37 | 36 | 73 |
| 2015 | 43 | 36 | 79 |
| 2016 | 59 | 33 | 92 |
| 2017 | 55 | 41 | 96 |
| 2018 | 58 | 18 | 76 |
| 2019 | 29 | 22 | 51 |
| 2020 | 38 | 32 | 70 |
| 2021 | 29 | 31 | 60 |
| 2022 | 9 | 48 | 57 |
| 2023 | 12 | 30 | 42 |
| 2024 | 28 | 17 | 45 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J Virol. 2024 Dec 17; 98(12):e0142924.
-
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. J Rheumatol. 2024 Nov 01; 51(11):1125-1134.
-
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec; 13(1):2402880.
-
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024 Sep 26; 391(12):1159-1162.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Desensitization with daratumumab in a pediatric patient with thalassemia major and high donor-specific antibody prior to haploidentical transplantation. Pediatr Blood Cancer. 2024 Nov; 71(11):e31311.
-
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
-
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc? receptors during acute SHIVAD8-EO infection. Nat Commun. 2024 Aug 29; 15(1):7461.